Bristol Myers Squibb (BMY) Net Cash Flow (2009 - 2026)

Bristol Myers Squibb has disclosed Net Cash Flow across 18 years of filings, most recently posting -$587.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 227.06% year-over-year to -$587.0 million; the TTM figure through Mar 2026 stood at -$1.4 billion (down 187.62% YoY), while the FY2025 annual figure was -$324.0 million, up 68.7% from the prior year.
• Net Cash Flow advanced to -$587.0 million in Q1 2026, from -$5.5 billion in the prior quarter.
• Over the last five years, Net Cash Flow for BMY reached as high as $3.9 billion in Q4 2023 and fell as low as -$5.5 billion in Q4 2025.
• The 5-year median for Net Cash Flow is -$587.0 million (2026), against an average of -$279.7 million.
• Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 2768.97% — and 2024, when it surged 285.59%.
• A 5-year view of Net Cash Flow shows it stood at $1.3 billion in 2022, then surged by 204.24% to $3.9 billion in 2023, then slumped by 32.84% to $2.6 billion in 2024, then tumbled by 311.96% to -$5.5 billion in 2025, then soared by 89.35% to -$587.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$587.0 million, -$5.5 billion, and $3.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.